Annals of Surgical Oncology

, Volume 19, Issue 3, pp 1024–1033 | Cite as

Clinicopathologic Features of Incident and Subsequent Tumors in Patients with Multiple Primary Cutaneous Melanomas

  • Rajmohan Murali
  • Chris Goumas
  • Anne Kricker
  • Lynn From
  • Klaus J. Busam
  • Colin B. Begg
  • Terence Dwyer
  • Stephen B. Gruber
  • Peter A. Kanetsky
  • Irene Orlow
  • Stefano Rosso
  • Nancy E. Thomas
  • Marianne Berwick
  • Richard A. Scolyer
  • Bruce K. Armstrong
  • For the GEM Study Group
Melanomas

Abstract

Background

0.6–12.7% of patients with primary cutaneous melanoma will develop additional melanomas. Pathologic features of tumors in patients with multiple primary cutaneous melanomas have not been well described. In this large, international, multicenter, case–control study, we compared the clinicopathologic features of a subsequent melanoma with the preceding (usually the first) melanoma in patients with multiple primary cutaneous melanomas, and with those of melanomas in patients with single primary cutaneous melanomas.

Methods

Multiple primary melanoma (cases) and single primary invasive melanoma (controls) patients from the Genes, Environment and Melanoma (GEM) study were included if their tumors were available for pathologic review and confirmed as melanoma. Clinicopathologic characteristics of invasive subsequent and first melanomas in cases and invasive single melanomas in controls were compared.

Results

A total of 473 pairs comprising a subsequent and a first melanoma and 1,989 single melanomas were reviewed. Forward stepwise regression modeling in 395 pairs with complete data showed that, compared with first melanomas, subsequent melanomas were more commonly contiguous with a dysplastic nevus, more prevalent on the head/neck and legs than other sites, and thinner. Compared with single primary melanomas, subsequent melanomas were more likely to be associated with a contiguous dysplastic nevus, more prevalent on the head/neck and legs, and thinner. The same differences were observed when subsequent melanomas were compared with single melanomas. First melanomas were more likely than single melanomas to have associated solar elastosis and no observed mitoses.

Conclusions

Thinner subsequent than first melanomas suggest earlier diagnosis, perhaps due to closer clinical scrutiny. The association of subsequent melanomas with dysplastic nevi is consistent with the latter being risk factors or risk markers for melanoma.

Keywords

Melanoma Prevalence Ratio Primary Melanoma Breslow Thickness Clark Level 

Notes

Acknowledgment

This work is supported by the following NIH/NCI grants: U01 CA83180, R01 CA112425, R01 CA112243, and R01 CA112243-05S1. Professor Scolyer is a Cancer Institute New South Wales Clinical Research Fellow.

References

  1. 1.
    Savoia P, Quaglino P, Verrone A, et al. Multiple primary melanomas: analysis of 49 cases. Melanoma Res. 1998;8(4):361–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Ferrone CR, Ben Porat L, Panageas KS, et al. Clinicopathological features of and risk factors for multiple primary melanomas. JAMA. 2005;294(13):1647–54.PubMedCrossRefGoogle Scholar
  3. 3.
    Uliasz A, Lebwohl M. Patient education and regular surveillance results in earlier diagnosis of second primary melanoma. Int J Dermatol. 2007;46(6):575–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Burden AD, Newell J, Andrew N, et al. Genetic and environmental influences in the development of multiple primary melanoma. Arch Dermatol. 1999;135(3):261–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Burden AD, Vestey JP, Sirel JM, et al. Multiple primary melanoma: risk factors and prognostic implications. BMJ. 1994;309(6951):375.PubMedCrossRefGoogle Scholar
  6. 6.
    Lucchina LC, Barnhill RL, Duke DM, et al. Familial cutaneous melanoma. Melanoma Res. 1995;5(6):413–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Gupta BK, Piedmonte MR, Karakousis CP. Attributes and survival patterns of multiple primary cutaneous malignant melanoma. Cancer. 1991;67(7):1984–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Moseley HS, Giuliano AE, Storm FK, 3rd, et al. Multiple primary melanoma. Cancer. 1979;43(3):939–44.PubMedCrossRefGoogle Scholar
  9. 9.
    Slingluff CL Jr, Vollmer RT, Seigler HF. Multiple primary melanoma: incidence and risk factors in 283 patients. Surgery. 1993;113(3):330–9.PubMedGoogle Scholar
  10. 10.
    Kang S, Barnhill RL, Mihm MC, Jr., et al. Multiple primary cutaneous melanomas. Cancer. 1992;70(7):1911–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Reimer RR, Clark WH Jr, Greene MH, et al. Precursor lesions in familial melanoma. A new genetic preneoplastic syndrome. JAMA. 1978;239(8):744–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Frank W, Rogers GS. Melanoma update. Second primary melanoma. J Dermatol Surg Oncol. 1993;19(5):427–30.PubMedGoogle Scholar
  13. 13.
    Pack GT, Scharnagel IM, Hillyer RA. Multiple primary melanoma. Cancer. 1952;5(6):1110–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Beardmore GL, Davis NC. Multiple primary cutaneous melanomas. Arch Dermatol. 1975;111(5):603–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Cascinelli N, Fontana V, Cataldo I, et al. Multiple primary melanoma. Tumori. 1975;61(5):481–6.PubMedGoogle Scholar
  16. 16.
    Scheibner A, Milton GW, McCarthy WH, et al. Multiple primary melanoma—a review of 90 cases. Australas J Dermatol. 1982;23(1):1–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Titus-Ernstoff L, Duray PH, Ernstoff MS, et al. Dysplastic nevi in association with multiple primary melanoma. Cancer Res. 1988;48(4):1016–8.PubMedGoogle Scholar
  18. 18.
    Ariyan S, Poo WJ, Bolognia J, et al. Multiple primary melanomas: data and significance. Plast Reconstr Surg. 1995;96(6):1384–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Giles G, Staples M, McCredie M, et al. Multiple primary melanomas: an analysis of cancer registry data from Victoria and New South Wales. Melanoma Res. 1995;5(6):433–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Marghoob AA, Slade J, Kopf AW, et al. Risk of developing multiple primary cutaneous melanomas in patients with the classic atypical-mole syndrome: a case-control study. Br J Dermatol. 1996;135(5):704–11.PubMedCrossRefGoogle Scholar
  21. 21.
    Brobeil A, Rapaport D, Wells K, et al. Multiple primary melanomas: implications for screening and follow-up programs for melanoma. Ann Surg Oncol. 1997;4(1):19–23.PubMedCrossRefGoogle Scholar
  22. 22.
    Johnson TM, Hamilton T, Lowe L. Multiple primary melanomas. J Am Acad Dermatol. 1998;39(3):422–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Monzon J, Liu L, Brill H, et al. CDKN2A mutations in multiple primary melanomas. N Engl J Med. 1998;338(13):879–87.PubMedCrossRefGoogle Scholar
  24. 24.
    Bhatia S, Estrada-Batres L, Maryon T, et al. Second primary tumors in patients with cutaneous malignant melanoma. Cancer. 1999;86(10):2014–20.PubMedCrossRefGoogle Scholar
  25. 25.
    DiFronzo LA, Wanek LA, Elashoff R, et al. Increased incidence of second primary melanoma in patients with a previous cutaneous melanoma. Ann Surg Oncol. 1999;6(7):705–11.PubMedCrossRefGoogle Scholar
  26. 26.
    Wolff J, Wollina U. Second malignancies in melanoma patients in Thuringia. J Eur Acad Dermatol Venereol. 2000;14(6):479–83.PubMedCrossRefGoogle Scholar
  27. 27.
    DiFronzo LA, Wanek LA, Morton DL. Earlier diagnosis of second primary melanoma confirms the benefits of patient education and routine postoperative follow-up. Cancer. 2001;91(8):1520–4.PubMedCrossRefGoogle Scholar
  28. 28.
    Schmid-Wendtner MH, Baumert J, Wendtner CM, et al. Risk of second primary malignancies in patients with cutaneous melanoma. Br J Dermatol. 2001;145(6):981–5.PubMedCrossRefGoogle Scholar
  29. 29.
    Stam-Posthuma JJ, van Duinen C, Scheffer E, et al. Multiple primary melanomas. J Am Acad Dermatol. 2001;44(1):22–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Blackwood MA, Holmes R, Synnestvedt M, et al. Multiple primary melanoma revisited. Cancer. 2002;94(8):2248–55.PubMedCrossRefGoogle Scholar
  31. 31.
    Doubrovsky A, Menzies SW. Enhanced survival in patients with multiple primary melanoma. Arch Dermatol. 2003;139(8):1013–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Goggins WB, Tsao H. A population-based analysis of risk factors for a second primary cutaneous melanoma among melanoma survivors. Cancer. 2003;97(3):639–43.PubMedCrossRefGoogle Scholar
  33. 33.
    Titus-Ernstoff L, Perry AE, Spencer SK, et al. Multiple primary melanoma: two-year results from a population-based study. Arch Dermatol. 2006;142(4):433–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Bower MR, Scoggins CR, Martin RC 2nd, et al. Second primary melanomas: incidence and outcome. American Surgeon. 2010;76(7):675–81.PubMedGoogle Scholar
  35. 35.
    Begg CB, Hummer AJ, Mujumdar U, et al. A design for cancer case-control studies using only incident cases: experience with the GEM study of melanoma. Int J Epidemiol. 2006;35(3):756–64.PubMedCrossRefGoogle Scholar
  36. 36.
    Barros AJ, Hirakata VN. Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res Methodol. 2003;3:21.PubMedCrossRefGoogle Scholar
  37. 37.
    Guerriere-Kovach PM, Hunt EL, Patterson JW, et al. Primary melanoma of the skin and cutaneous melanomatous metastases: comparative histologic features and immunophenotypes. Am J Clin Pathol. 2004;122(1):70–7.PubMedCrossRefGoogle Scholar
  38. 38.
    Orlow I, Tommasi DV, Bloom B, et al. Evaluation of the clonal origin of multiple primary melanomas using molecular profiling. J Invest Dermatol. 2009;129(8):1972–82.PubMedCrossRefGoogle Scholar
  39. 39.
    Manganoni AM, Farisoglio C, Tucci G, et al. The importance of self-examination in the earliest diagnosis of multiple primary cutaneous melanomas: a report of 47 cases. J Eur Acad Dermatol Venereol. 2007;21(10):1333–6.PubMedCrossRefGoogle Scholar
  40. 40.
    Allen AC, Spitz S. Malignant melanoma: a clinicopathological analysis of the criteria for diagnosis and prognosis. Cancer. 1953;6(1):1–45.PubMedCrossRefGoogle Scholar
  41. 41.
    Rigel DS, Friedman RJ, Kopf AW, et al. Importance of complete cutaneous examination for the detection of malignant melanoma. J Am Acad Dermatol. 1986;14(5 Pt 1):857–60.PubMedCrossRefGoogle Scholar
  42. 42.
    Carli P, De Giorgi V, Chiarugi A, et al. Multiple synchronous cutaneous melanomas: implications for prevention. Int J Dermatol. 2002;41(9):583–5.PubMedCrossRefGoogle Scholar
  43. 43.
    Poo-Hwu WJ, Ariyan S, Lamb L, et al. Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma. Cancer. 1999;86(11):2252–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Green A, MacLennan R, Youl P, et al. Site distribution of cutaneous melanoma in Queensland. Int J Cancer. 1993;53(2):232–6.PubMedCrossRefGoogle Scholar
  45. 45.
    Whiteman DC, Bray CA, Siskind V, et al. A comparison of the anatomic distribution of cutaneous melanoma in two populations with different levels of sunlight: the west of Scotland and Queensland, Australia 1982–2001. Cancer Causes Control. 2007;18(5):485–91.PubMedCrossRefGoogle Scholar
  46. 46.
    Kricker A, Armstrong BK, Goumas C, et al. Ambient UV, personal sun exposure and risk of multiple primary melanomas. Cancer Causes Control. 2007;18(3):295–304.PubMedCrossRefGoogle Scholar
  47. 47.
    Duncan LM. The classification of cutaneous melanoma. Hematol Oncol Clin North Am. 2009;23(3):501–13, ix.Google Scholar
  48. 48.
    Balch CM, Wilkerson JA, Murad TM, et al. The prognostic significance of ulceration of cutaneous melanoma. Cancer. 1980;45(12):3012–7.PubMedCrossRefGoogle Scholar
  49. 49.
    Lock-Andersen J, Hou-Jensen K, Hansen JP, et al. Observer variation in histological classification of cutaneous malignant melanoma. Scand J Plast Reconstr Surg Hand Surg. 1995;29(2):141–8.PubMedCrossRefGoogle Scholar
  50. 50.
    Corona R, Mele A, Amini M, et al. Interobserver variability on the histopathologic diagnosis of cutaneous melanoma and other pigmented skin lesions. J Clin Oncol. 1996;14(4):1218–23.PubMedGoogle Scholar
  51. 51.
    Crutcher WA, Sagebiel RW. Prevalence of dysplastic naevi in a community practice. Lancet. 1984;1(8379):729.PubMedCrossRefGoogle Scholar
  52. 52.
    Greene MH, Clark WH Jr, Tucker MA, et al. High risk of malignant melanoma in melanoma-prone families with dysplastic nevi. Ann Intern Med. 1985;102(4):458–65.PubMedGoogle Scholar
  53. 53.
    Tucker MA, Fraser MC, Goldstein AM, et al. Risk of melanoma and other cancers in melanoma-prone families. J Invest Dermatol. 1993;100(3):350S–5S.PubMedCrossRefGoogle Scholar
  54. 54.
    Carey WP, Jr., Thompson CJ, Synnestvedt M, et al. Dysplastic nevi as a melanoma risk factor in patients with familial melanoma. Cancer. 1994;74(12):3118–25.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2011

Authors and Affiliations

  • Rajmohan Murali
    • 1
    • 2
    • 3
    • 14
  • Chris Goumas
    • 4
  • Anne Kricker
    • 2
    • 4
  • Lynn From
    • 5
  • Klaus J. Busam
    • 6
  • Colin B. Begg
    • 7
  • Terence Dwyer
    • 8
  • Stephen B. Gruber
    • 9
  • Peter A. Kanetsky
    • 10
  • Irene Orlow
    • 7
  • Stefano Rosso
    • 11
  • Nancy E. Thomas
    • 12
  • Marianne Berwick
    • 13
  • Richard A. Scolyer
    • 1
    • 2
    • 3
  • Bruce K. Armstrong
    • 2
    • 4
  • For the GEM Study Group
  1. 1.Tissue Pathology and Diagnostic OncologyRoyal Prince Alfred HospitalSydneyAustralia
  2. 2.Melanoma Institute AustraliaSydneyAustralia
  3. 3.Discipline of PathologyThe University of SydneySydneyAustralia
  4. 4.School of Public Health, Sydney Medical SchoolThe University of SydneySydneyAustralia
  5. 5.Women’s College HospitalTorontoCanada
  6. 6.Department of PathologyMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  7. 7.Department of Epidemiology and BiostatisticsMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  8. 8.Murdoch Children’s Research InstituteRoyal Children’s HospitalMelbourneAustralia
  9. 9.Division of Molecular Medicine & GeneticsUniversity of MichiganAnn ArborUSA
  10. 10.University of Pennsylvania School of MedicinePhiladelphiaUSA
  11. 11.CPO-Registro Tumori PiemonteTurinItaly
  12. 12.Department of Dermatology, Lineberger Comprehensive Cancer CenterUniversity of North CarolinaChapel Hill USA
  13. 13.Division of Epidemiology and BiostatisticsUniversity of New MexicoAlbuquerqueUSA
  14. 14.Human Oncology and Pathogenesis ProgramMemorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations